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ABSTRACT

Objective. The Miami Heart Study (MiHeart) at Baptist Health South Florida is an ongoing, communitybased, prospective cohort study aimed at characterizing the prevalence, characteristics, and prognostic
value of diverse markers of early subclinical coronary atherosclerosis and of various potential
demographic, psychosocial, and metabolic risk factors. We present the study objectives, detailed
research methods, and preliminary baseline results of MiHeart.
Methods. MiHeart enrolled 2,459 middle-aged male and female participants from the general
population of the Greater Miami Area. Enrollment occurred between May 2015 and September 2018
and was restricted to participants aged 40–65 years free of clinical cardiovascular disease (CVD). The
baseline examination included assessment of demographics, lifestyles, medical history, and a detailed
evaluation of psychosocial characteristics; a comprehensive physical exam; measurement of multiple
blood biomarkers including measures of inflammation, advanced lipid testing, and genomics;
assessment of subclinical coronary atherosclerotic plaque and vascular function using coronary
computed tomography angiography, the coronary artery calcium score, carotid intima-media thickness,
pulse wave velocity, and peripheral arterial tonometry; and other tests including 12-lead
electrocardiography and assessment of pulmonary function. Blood samples were biobanked to facilitate
future ancillary research.
Results. MiHeart enrolled 1,261 men (51.3%) and 1,198 women (48.7%). Mean age was 53 years, 85.6%
participants were White and 47.4% were of Hispanic/Latino ethnicity. The study included 7% individuals
with diabetes, 33% with hypertension, and 15% used statin therapy at baseline. Overweight or obese
participants comprised 72% of the population and 3% were smokers. Median 10-year estimated
atherosclerotic CVD risk using the Pooled Cohort Equations was 4%.
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Conclusion. MiHeart will provide important, novel insights into the pathophysiology of early subclinical
atherosclerosis and further our understanding of its role in the genesis of clinical CVD. The study findings
will have important implications, further refining current cardiovascular prevention paradigms and risk
assessment and management aproaches moving forward.

KEYWORDS
atherosclerosis; cardiovascular disease; cohort studies; coronary computed tomography; epidemiology;
Hispanic/Latino; populations; primary prevention

ABBREVIATIONS AND ACRONYMS
BHSF

Baptist Health South Florida

CAC

coronary artery calcium

CCTA

coronary computed tomography angiography

CIMT

carotid intima media thickness

CT

computed tomography

CVD

cardiovascular disease

EDTA

ethylenediaminetetraacetic acid

IRB

Institutional Review Board

MESA

Multi-Ethnic Study of Atherosclerosis

MiHeart

Miami Heart Study

NHW

non-Hispanic Whites

Introduction
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and
accounts for a large share of total health care expenditure.1–3 While CVD risk assessment in general has
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been traditionally guided by risk estimates derived from scores combining traditional risk factors, there
is a growing body of evidence showing that such an approach lacks sufficient accuracy in predicting risk
of future events among asymptomatic individuals.4–9 Consequently, in recent years there has been a
considerable interest in a paradigm change in the approach to primary CVD prevention, expanding the
focus from surrogate risk factors alone to also assess the disease process itself.10,11 In this regard,
detection of atherosclerosis via subclinical disease assessment provides information about the actual
disease burden, and as such, performs better than surrogate biomarkers.4,10–17
A robust, low-radiation, relatively inexpensive marker of atherosclerotic coronary artery disease,
the coronary artery calcium (CAC) score is now a guideline-endorsed test for further risk assessment.11
CAC has consistently shown powerful predictive value beyond conventional cardiac risk factors in
asymptomatic individuals in multiple population-based cohorts.4,12–17 Although CAC is an excellent
marker of underlying coronary atherosclerosis, it does not capture the whole spectrum of plaque
morphology and plaque burden.18,19 Indeed, the coronary calcified plaque burden has been shown to
represent only 20% of the total plaque burden, as coronary atherosclerosis is mostly lipid-laden or
fibrous.20,21
In addition, significant gaps remain in scientific knowledge with regards to the relationship
between multiple lifestyle factors, genetic and metabolic risk factors and biomarkers, and early plaque
biology. The analysis of these associations has so far been hampered by lack of accurate and welldefined atherosclerotic phenotypes in clinical settings in asymptomatic populations. Coronary computed
tomography angiography (CCTA) is a noninvasive technique for the evaluation of the coronary anatomy,
stenosis, and the characterization of atherosclerotic plaques.18,22–27 Until now, the presence, burden and
differential architectural features of atherosclerotic plaque in the coronary arteries has remained
unexplored in large populations of asymptomatic individuals. This is particularly true in populations of
young to middle-aged asymptomatic individuals, who may at priority be considered at low risk for
cardiovascular events. In such a population, CCTA may allow for the assessment of the early stages of
coronary atherosclerosis, facilitating the identification of its key determinants.
The Miami Heart Study (MiHeart) at Baptist Health South Florida (BHSF) is an ongoing,
community-based, prospective cohort study of individuals from the general population free of clinical
CVD. MiHeart is aimed at characterizing the presence, features, architecture as well as prognostic ability
of earliest diverse markers of subclinical coronary atherosclerotic disease in a population-based cohort
of young- and middle-aged men and women free of established CVD; and for this purpose, all
participants underwent CCTA at the study baseline. In this article we describe the underlying rationale,
study objectives, methods used, and preliminary baseline results of MiHeart.

Study Objectives
The primary objectives of MiHeart are to: 1) assess and characterize the presence and severity
of subclinical CVD burden among middle-aged asymptomatic individuals; and 2) determine relationships
4

of traditional risk factors, lifestyle and behavioral factors as well and biomarkers (traditional and novel)
related to presence and burden of subclinical CVD among middle-aged asymptomatic individuals.
The secondary study objectives are to: 3) determine the interplay of risk factors (traditional,
lifestyle, biomarkers) and early markers of subclinical CVD with the development of clinical CVD; 4)
determine relationships of traditional risk factors, lifestyle and behavioral factors as well and biomarkers
(traditional and novel) related to presence and burden of subclinical CVD among middle-aged
asymptomatic individuals; and 5) develop population-based methods, suitable for application in future
screening and intervention studies, for characterizing cardiovascular risk among middle-aged
asymptomatic persons as well cost effectiveness for such paradigms in appropriately resource allocation
for early CVD management.

Methods
Study Design and Population
MiHeart (clinicaltrials.gov identifier NCT0250845428) is an observational, community-based,
longitudinal, prospective cohort study that included 2,459 middle-aged male and female participants
from the population of the Greater Miami Area (Figure). Study recruitment was based on volunteer
participation. Since the study is primarily concerned with the determinants and natural history of
subclinical CVD, the age range of the study population was set between 40 to 65 years, and participants
with known clinical CVD were excluded from the study.
The specific study inclusion and exclusion criteria are listed in Table 1. Besides the criteria
described above, additional exclusion criteria referred to contraindications for computed tomography
(CT) testing or other study procedures, active cancer, and inability to provide consent for participation.
Both prevalent CVD and the rest of inclusion and exclusion criteria were determined exclusively on the
basis of self-reported information provided by the study participants; no attempts were made to
validate the participant’s response(s) as this is the standard set by prior cohort studies.
Research Ethics
The study protocol was reviewed and approved by the Institutional Review Board (IRB) of BHSF.
All study procedures adhered to the principles included in the Declaration of Helsinki.29 All participants
provided written informed consent prior to study entry, and potential participants unable to
comprehend and sign an informed consent form were excluded. The same was true for potential
participants who failed to provide written consent for whichever reason. As BHSF is a sponsor of this
study, additional strategies with IRB guidance were implemented to minimize potential ethics risks (e.g.,
privacy) associated with employee-participants.
Recruitment Strategy
The principal investigator and research staff were responsible for creating recruitment strategies
which complied with both BHSF and federal regulations. The purpose, rationale, and design of the study
5

was publicized to targeted groups in Baptist Health and community members of South Florida (table 2).
The efforts included mailings of letters and brochures, posters, newspaper and radio advertisement as
well as detailed on the study website (MiamiHeartStudy.net) followed by personal contacts via
telephone, email, or in person. The marketing and advertising materials tailored to meet unique aspects
of the source population and recruitment strategy were submitted to the IRB for approval prior to
implementation tailored to meet unique aspects of the source population and recruitment strategy.
Baseline Data Collection
The baseline study examination took place between May 2015 and September 2018. As shown
in Table 3, the baseline study examination included 1) a detailed assessment of self-reported
cardiovascular risk factors, including demographic characteristics, medical history, medication use,
lifestyle characteristics, and psychosocial factors; 2) a detailed physical exam, which included vitals and
anthropometric measurements; 3) blood sampling for determination of biomarker assessment,
advanced “omics” and biobanking; 4) assessment of subclinical atherosclerotic plaque, and vascular
dysfunction; and 5) other tests, such as 12-lead electrocardiography, and assessment of pulmonary
function.
Study survey and questionnaires were administered via RedCap survey after online consent
prior to clinic visit (Table 4). For participants unable to fill the questionnaires prior to their study visit,
access to computers and to a paper version of the survey was provided at their clinic visit. Both English
and Spanish versions were available
Vitals: All participants had their temperature, heart rate, systolic and diastolic blood pressure,
and respirations per minute taken and recorded using standard procedures. Specifically, for blood
pressure, subjects were asked to sit quietly and rest for 5 minutes with their legs uncrossed, and an
OMRON automatic blood pressure monitor (model BP710) was used. Three separate readings were
taken at intervals of at least 1 minute
Anthropometric measurements: Participants were weighed on a calibrated scale, without shoes
and with all pockets emptied. The results were recorded to the nearest 0.2 kilograms. Height was
measured in meters using the SECA 213 measuring system. The body mass index was computed as
weight (kg) / (height [m] x height [m]). Waist circumference was measured at the top of the iliac crest
using a K-E anthropometric tape positioned in a horizontal plane around the abdomen, applying tension
to the tape to ensure it was snug yet without causing indentation to the skin. The measurement was
performed at the end of a normal expiration. The hip circumference was measured at the level of the
greatest girth—typically the level of the trochanters. Both measurements were made to the nearest 0.5
cm. The waist to hip ratio was then computed as waist circumference (cm) / hip circumference (cm).
Body fat percentage was measured using a hand-held body fat analyzer (OMRON Fat Loss Monitor
Model HBF-306C). Subjects held the monitor with their arms straight out at a 90 degrees angle to their
body. The device provided a percent fat estimate on the basis of measurements using the bioelectrical
impedance method combined with inputs on the subjects’ age, sex, weight and height.
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ECG: For electrocardiography, three 12-lead recordings were obtained using Welch Allyn
standard digital 12-lead ECG.
Spirometry: Spirometry measurements were obtained using the Welch Allyn spirometry
machine. Welch Allyn disposable flow transducers were used and three measurements were made
during rapid and forceful exhalation.
Endothelial function: Peripheral arterial tone signal was used to measure, non-invasively,
arterial tone changes in peripheral arterial beds, using the Itamar EndoPat 2000 system. Both the
Reactive Hyperemia Index (RHI), a measure of endothelial function, and the Augmentation Index (AI), a
measure of arterial stiffness, were measured. The test involved baseline measurement with the EndoPat
probe on the index finger for 5 minutes. A blood pressure cuff was then applied on the non-dominant
arm for next 5 minutes to occlude blood supply, and a recording is done during this phase. After 5
minutes of occlusion to the non-dominant arm, the pressure is released. Once the blood flow is restored
resulting in blood vessels to dilate, the EndoPat machine calculates the stiffness in the arterial walls. The
vessel wall reactivity is the comparison of the pre-occlusion and post-occlusion blood flow and is
reported as reactive hyperemia index.
Carotid intima-media thickness (CIMT) was measured using the Panasonic CardioHealth Station
automated carotid ultrasound device. Using a single transducer angle, fully automated CIMT
measurements were recorded. The mean CIMT measurement is defined as the mean of 24 spatial
measurements performed over a 1-cm region in the far wall of the common carotid artery. In addition,
presence of any atherosclerotic coronary plaque was defined as any obvious focal luminal
encroachment >1.00 mm.
Pulse Wave Analysis: Pulse wave analysis and pulse wave velocity measurements were obtained
using AtCor Medical SphygmoCor XCEL machine. It used a standard brachial cuff to measure brachial
systolic and diastolic pressures and capture a brachial waveform. The brachial waveform was then
analyzed by SphygmoCor to provide a central aortic waveform. Noninvasive central blood pressure
measurements such as central aortic systolic blood pressure, central pulse pressure, and an aortic
augmentation index (AIx) were also reported. Pulse wave velocity was measured using a carotid
tonometer simultaneously with a leg cuff to capture blood pressure waveforms at the carotid and
femoral sites.
Coronary CT: In all participants, a non-contrast cardiac-gated CT scan for CAC testing was
performed prior to conducting a contrast-enhanced, cardiac-gated CCTA. Both contrast and non-contrast
scans were performed using GE Revolution (GE Healthcare) scans. Before the test, study participants
received oral and/or intravenous β-blocker (metoprolol) as needed to achieve a heart rate of <75 beats per
minute. Additionally, 0.4mg of sublingual nitroglycerine was given immediately before angiographic
image acquisition. The radiation dose was estimated from the dose-length product multiplied by the
conversion factor (0.014 mSv/mGy • cm). Assessment of 17 segment plaque presence/burden and
classification was performed at a central core imaging lab.
7

Laboratory analyses and biobanking: In each participant, 97.5 ml of fasting blood were collected
at baseline (approximately ~53 aliquots per participant) for serum, plasma and whole blood. Samples
were tested for a wide range of biomarkers (Table 5). In addition, blood aliquots were bio-banked and
maintained at -80°C for future ancillary analyses. One 7.5 ml SST vacutainer drawn is left at room
temperature for 20-30 minutes for clotting before centrifugation at 3600xg for 15 minutes. After
centrifugation, serum is removed from SST vacutainer. It is aliquoted in 2 ml Starstedt microtubes
creating four aliquots. Six 10 ml red top vaccutainers are drawn and allowed to clot at room temperature
before centrifugation. If a patient opted out of biobanking then only five red top vaccutainers are drawn.
They are also centrifuged at 3600xg for 15 minutes. The serum is then aliquoted into 40 2ml Starstedt
tubes with each tube containing 0.75 ml serum. One 4ml Na+ Heparin vacutainer is drawn and then
centrifuged at 3600xg for 15 minutes within one hour of blood draw. It is then aliquoted in 0.75 ml
volumes into 2ml Starstedt tubes creating 2 aliquot tubes. Two 10 ml ethylenediaminetetraacetic acid
(EDTA) vacutainers are drawn which are also centrifuged at 3600xg for 15 minutes within one hour of
blood draw. The serum is then aliquoted into 12 2 ml Starstedt tubes with each tube containing 0.75 ml
serum. Additionally, three 2ml K2 EDTA tubes are drawn for every participant. If the subject opted out of
genetic testing, then only one 2 ml K2 EDTA tube is drawn. These K2 EDTA tubes are not centrifuged
and are stored as whole blood. All blood specimens are then stored at -80 C.

Data Management
All MiHeart data are collected and stored using the Research Electronic Data Capture (REDCap)
electronic data capture software, which is widely used for research purposes at Baptist Health South
Florida and elsewhere. REDCap is a secure, web-based application designed to support data collection
for research studies. Only authorized study personnel have access to the study data, and the study
datasets undergo periodic quality control checks by the database administrator and study coordinators.
Additionally, all study data undergo periodic audits by the IRB at Baptist Health South Florida.

Results
MiHeart enrolled 2,459 participants free of clinical CVD at baseline, including 1,261 (51.3%) men
and 1,198 women (48.7%). Mean age was 53 years, the majority of study participants were White
(85.6%), and 1,166 (47.4%) were of Hispanic/Latino ethnicity.
The baseline sociodemographic and clinical characteristics of the study population are
summarized in Table 6. More than 72% participants were either overweight or obese, while only 3%
were current smokers. Approximately 7% had diabetes, 33% hypertension, and 15% used statin therapy
at baseline. Median 10-year estimated atherosclerotic CVD risk using the Pooled Cohort Equations was
4%. Compared with 2010 US Census data for the population of Miami (Table 1), the MiHeart study
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population had a similar proportion of women (50.2% in Miami vs. 48.7% in MiHeart), and a lower
proportion of Hispanic/Latino participants (65% vs. 47.4%). Compared with the demographics of the
BHSF workforce, the proportion of women was markedly lower in MiHeart, while the proportion of
Hispanic/Latinos was identical.

Discussion
MiHeart is a large, ongoing, community-based, prospective cohort study of men and women
aged 40 to 65 years who underwent a comprehensive phenotyping of traditional and novel
cardiovascular risk factors, and diverse measurements of subclinical CVD. So far, to the best of our
knowledge no large US prospective study has conducted a baseline CCTA assessment of the study
population. MiHeart will provide a comprehensive evaluation of coronary plaque burden, subtypes,
morphology, and vulnerability features in a community-based primary prevention cohort. These unique
data from MiHeart will generate invaluable opportunities for groundbreaking research, enhancing our
understanding of the natural history of CVD, the early stages of subclinical atherosclerosis, and the key
underlying social, lifestyle and metabolic determinants.
Prior landmark multi-ethnic cardiovascular cohorts such as the Multi-Ethnic Study of
Atherosclerosis (MESA) or the Dallas Heart Study restricted their baseline assessment of coronary
atherosclerosis to CAC.30–34 While CAC has demonstrated an excellent performance as a tool for further
risk assessment in middle-aged individuals, whether the inability of non-contrast CT to detect noncalcified plaque may limit its performance for risk prediction in younger adults, or whether a CAC score
of zero may be less reassuring in this age group, remain unclear. It must be noted, however, that as of
2021 the Agatston score, which was developed in 1990,35 has not been replaced by more modern
measurements of plaque morphology or high-risk plaque features that can be measured with CCTA.18,22–
27

MiHeart is a natural extension of existing cohorts, like MESA, which with more than 2,000
publications has provided significant insights into the role of atherosclerosis imaging with CAC in guiding
risk assessment and subsequent management mostly in middle-aged individuals.13–15,30–34 In spite of
notable improvements in our understanding of the significance of atherosclerotic processes to date, in
studies such as MESA, the role of non-invasive atherosclerotic plaque imaging tools has been restricted
to an older subset of middle-aged individuals (usually aged 60 and above) and limited to CIMT and
CAC.30–34 With advances in contrast enhanced multi-detector CT we have now significantly improved our
ability to non-invasively obtain comprehensive information not only based on presence and burden, but
also accounting for characteristics of coronary atherosclerotic plaques to form the basis of more
advanced and contemporary indices of atherosclerotic disease assessment. MiHeart will be the first
prospective multi-ethnic population-based cohort study of a younger population free of clinical CVD
undergoing CCTA testing. This information will provide detailed insights on burden and plaque
characteristics in earlier stages of atherosclerosis, along with the characterization of biomarkers that can
identify high-risk individuals at an early stage. This has been relatively unexplored, particularly in
9

populations of (relatively) younger asymptomatic individuals (age 40-65 years) who may initially be
considered at low-risk for cardiovascular events.
Furthermore, with robust core lab based plaque assessment protocols, strict quality control
measures and leveraging our stored biobank, MiHeart will further our understanding of the
pathogenesis of atherosclerosis and other CVDs by (1) providing more accurate and quantifiable
measures of subclinical CVD among (younger) middle-aged asymptomatic individuals; (2) characterizing
earliest changes of atherosclerosis (when it may be subjected to interventions that disrupt the natural
history and progression of the disease); prior to clinical manifestation; (3) allowing for discovery and
validation of accurate and reliable biomarkers for early atherosclerotic disease so that they can be
rapidly translated into everyday clinical practices and (4) allowing comparisons among groups at
different levels of risk that may provide clues to pathogenesis.
Another distinguishing feature is that MiHeart enrolled participants from most racial/ethnic
groups in the US, including a large representation of the two largest groups—non-Hispanic Whites
(NHWs) and Hispanics/Latinos.36 While NHWs have been included in numerous American cardiovascular
studies since the landmark Framingham study,37 prospective cardiovascular research in
Hispanics/Latinos has been more limited. With a population of 60.6 million in 2019, Hispanics/Latinos
have become the largest minority group in the United States.36,38 With evidence of increasing burden of
ASCVD risk factors among Hispanics/Latinos in the US,39,40 there is a need to better understand the key
determinants of disease in this large, rapidly growing demographic group. MiHeart will generate very
important insights on the early stages of atherosclerosis in a large, rapidly growing group in the US.

Limitations
Some potential challenges are worth discussing. First, compared to the racial/ethnic distribution
of the US population, NHWs are underrepresented in MiHeart. Although this is consistent with the
specific demographic characteristics of the Greater Miami Area (according to the 2010 US Census,41 only
12% were NHWs, and researchers will have to account for the large proportion of Hispanic/Latino
participants in MiHeart when drawing conclusions to the general US population from analyses not
stratified by race/ethnicity. This may have implications for risk factor and plaque burden findings, as well
as for their prognostic implications. Second, follow-up is initially planned to last only 5 years. However,
there are ongoing efforts to secure additional funding to further extend the follow-up to 10 or more
years. Also, efforts are also ongoing to fund a second, repeat CCTA measurement over time, which will
allow to evaluate changes in plaque characteristics over time and define the key baseline determinants.

Conclusion
MiHeart at BHSF will provide important new information about the pathophysiology of early
subclinical disease development and its role in clinical CVD. The study has the potential to identify new
risk factors, discover/validate novel biomarkers (metabolic and genetic) for the earliest and highest risk
10

plaques in younger asymptomatic individuals and, therefore, increase the ability to predict CVD and,
ultimately, to design new interventions to prevent CVD. The multiethnic composition of the study
population is a major strength of the study, allowing comparisons that may provide unique insights
about new risk factors and subclinical disease, and opening the possibility of tailoring prevention efforts
according to ethnic differences in disease processes. The results of the study will be applicable to clinical
practice by identifying noninvasive subclinical disease measures that best predict risk and by suggesting
new approaches to interventions that prevent progression of subclinical disease and its transformation
to clinical disease. Findings may be directly applicable to clinical practice, may be used to design clinical
trials or optimize interventions, and/or may lead to research resulting in new methods of intervention.
Wellness programs may be able to utilize the study findings to better target and optimize CVD
prevention efforts.
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FIGURE LEGENDS
Figure. Study timeline, Miami Heart Study.
Abbreviations: CVD = cardiovascular disease

Central Illustration. Study design, Miami Heart Study.
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TABLES
Table 1. Study participant enrollment criteria, Miami Heart Study.
Inclusion Criteria


Current full time/part-time employees of BHSF (occupational cohort) or resident of
Greater Miami Area for at least six months (community cohort)



Age 40 to 65 years



Asymptomatic individuals free of any known clinically overt cardiovascular disease



Able to comprehend and sign an informed consent form

Exclusion Criteria


Prior history of major cardiovascular events (angina, myocardial infarction, prior
coronary revascularization)



History of cerebrovascular disease including stroke and transient ischemic attack



History of peripheral arterial disease



History of either diagnosis or surgery for abdominal aortic aneurysm



History of heart failure



Weight greater than 350 lbs



Any contraindication for computed tomography scanning or non-iodinated contrast
(BHSF West Kendall computed tomography angiography Imaging
Screening/Prerequisites/Methods)



Active treatment for cancer



Currently pregnant, breastfeeding, seeking to become pregnant, or suspect they may
be pregnant.



Patients who do not agree to provide informed consent

Potential participants who responded “Don’t know” to questions about medical conditions were not be
considered ineligible.
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Abbreviations: BHSF = Baptist Health South Florida

Table 2. Recruitment strategies, Miami Heart Study.
BHSF Employees
A. Study information was placed on the BHSF intranet site, Employee Newsletter,
Pineapple Press, Leaders Edge, and The Wellness Advantage and Research Matters
newsletter

B. Monthly email blasts from the Wellness Prevention distribution group sent to all
BHSF employees
C. Advertising materials distributed at Town Hall meetings at BHSF entities
D. Lunch & Learn Presentations throughout BHSF entities by the principal investigator
and coinvestigators

E. Study team members with designated table at Wellness Advantage Fairs &
Programs, BHSF CME conferences/symposiums, BHSF community events and
BHSF leadership retreats

F. Study team members partnered with BHSF Employee Advisory Group and the
Employee Activity Committee at scheduled employee events and activities to recruit
employees
G. Physician Relations newsletters & Medical Memo
H. Wellness Advantage fitness and education programs for employees
I. Digital signage (advertisement on entity televisions) throughout all BSHF entities
Non BHSF employees/Community members
A. Community outreach programs such as the West Kendall Initiative
B. Web postings (internet, baptisthealth.net) with link to the study website
MiamiHeartStudy.com. Study information was also placed on Centerwatch.com and
ClinicalTrials.gov
C. Study team members utilized the following BHSF publications: Resource, Baptist
Salud & Women’s Health Resource Newsletter
D. BHSF Community Health’s education, screening and exercise programs as well as
the “Healthy West Kendall Initiative”
E. West Kendall Baptist Hospital community events throughout the year to
disseminate study information
F. Partner with BHSF physician relations representative throughout BHSF entities to
post recruitment materials in physician offices
G. Subject & Physician Recruitment Letters
H. Social Media: Facebook, Twitter, Instagram
17

I. Posting & distributing recruitment materials throughout local pharmacies
and grocery stores as well as local gyms & fitness centers in the greater Miami area
J. Radio ads in English/Spanish
K. Movie theater story board – English only

Abbreviations: BHSF = Baptist Health South Florida; CME = continued medical education
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Table 3. Schedule of procedures and data collection in the Miami Heart Study.
Procedure

Baseline

Enrollment and informed consent

X

Lifestyle, diet and behavior questionnaires

X

Vitals

X

Anthropometric measurements

X

12-lead ECG

X

Spirometry

X

Endothelial function assessment

X

Carotid ultrasound/Intima-media thickness measurement

X

CT coronary calcium scoring/CT angiography

X

Laboratory analysis

X

Biobanking

X

Pulse wave analysis

X

Follow-up for clinical events

Yearly Follow-up

X

Abbreviations: CT = computed tomography; ECG = electrocardiogram
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Table 4. Baseline questionnaires and surveys, Miami Heart Study.
Questionnaire

Description/Items Assessed

Anxiety

General Anxiety Disorder7-item scale (GAD-7)

Demographics

Age, Gender, Race, Ethnicity, Language, Education,
Employment, Marital Status, Socio-economic status

Depression

Modified Patient Health Questionnaire (PHQ-9)

Diet

Food Frequency Questionnaire, Food Access Survey

Lung Function

Assessment of Coughing, Wheezing, Shortness of Breath,
Inhibition of ADL’s

Medical & Family History

Conditions related to heart and vascular disorders, lung and
breathing related disorders, gastrointestinal disorders,
endocrine, hematologic, mental health, eye, rheumatologic &
dermatologic disorders, reproductive history, cancer, family
medical history

Medication History

Prescription and non-prescription medication use,
vitamin/dietary supplements and alternative medications

Mental Health Continuum

Feelings of happiness, confidence, satisfaction with life, and
belonging

Mindfulness

Assessment of spiritual and mental awareness and presence

Physical Activity

Current physical activity including work, household, leisure,
sport related activity, sedentary behavior

Sleep

Snoring, Tiredness (Berlin Questionnaire), Daytime sleepiness
(Epworth Sleepiness), Sleep quality (Pittsburgh Sleep Quality
Index)

Smoking, Caffeine
Consumption

Past and current cigarette use, ever use of cigars and pipes,
use of modified harm-reduction tobacco products, exposure
to secondhand smoke. Current consumption of caffeinated
products on a daily basis
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Alcohol Use

Usual intake and drinking patterns.

Social Support

Available and perceived social support, emotional support,
help with chores, someone who will listen, etc

Spirituality

Feelings of peace, purpose, finding strength and comfort in
faith (FACIT-12)

Stress

Perceived stress scale, stress in the workplace
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Table 5. Baseline laboratory analyses, Miami Heart Study.
Group of measurements
Cardiac Enzymes

Specific measurements


N-terminal pro b-type natriuretic peptide (NT-ProBNP)

(pg/mL)
Hemostasis and Fibrinolysis



D-Dimer (mcg/mL)

Inflammation



High sensitivity C-reactive protein (hs-CRP) (mg/L)





Interleukin-2 (IL-2) (pg/mL)
Interleukin-6 (IL-6) (pg/mL)





Whole Blood Hemoglobin A1c (HbA1c)
Serum Insulin (uIU/mL)

Endothelial Cell Function



Homocysteine (umol/L)

Lipids



Cholesterol (mg/dL), Total, High-Density Lipoprotein
(HDL), Low-Density Lipoprotein (LDL), Triglycerides
Ion Mobility: Lipid size, distribution, subclasses
Apolipoprotein B (ApoB) (mg/dL)
Lipoprotein (a) (Lp[a]) (nmol/L)
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
(nmol/min/mL)

Diabetes






Tumor Necrosis Factor (TNF) alpha (pg/mL)

Free Fatty Acid (mmol/L)

Nutrition



Omega-3 and Omega-6 Fatty Acids

Genetics







ApoE Genotype

Obesity/Metabolism




Leptin (ng/mL)
Adiponectin (mcg/mL)

Renal Function




Cystatin-C (mg/L)
Aldosterone (ng/dL)

9p21 Genotype
KIF6 Genotype
LPA Intron 25
4q25 A-Fib genotype
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Sex Hormones






Testosterone, Free (pg/mL) &Total (ng/dl),
Dehydroepiandrosterone (ng/dL)
Estradiol (pg/mL)
Sex Hormone Binding Globulin (nmol/L)

Vitamins and Minerals






1, 25 Dihydroxy Vitamin D (pg/mL)
25-Hydroxyvitamin D [25(OH)D] (ng/mL)
Thyroid Stimulating Hormone (TSH) (mIU/L)
Parathyroid Hormone, Related Protein (PTH-RP)
(pg/mL)
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Table 6. Baseline characteristics of the study population, Miami Heart Study.

MiHeart Study (N=2,459)
Demographics
Age, years

53.35 (6.78)

Women

1,198 (48.7%)

Race
White

2,104 (85.6%)

Black

94 (3.8%)

Asian

74 (3%)

Other

186 (7.6%)

Ethnicity
Hispanic/Latino

1,166 (47.4%)

Not Hispanic/Latino

1,255 (51%)

Other cardiovascular risk factors
Body mass index, kg/m2

28.45 (5.29)

Body mass index categories
Normal weight

679 (27.6%)

Overweight

991 (40.3%)

Obesity

789 (32.1%)

Family history of CVD

707 (28.8%)

Family history of premature CVD

185 (7.5%)

Tobacco use
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Current smoker

75 (3.1%)

Former smoker

602 (24.5%)

Never smoker

1,782 (72.5%)

Diabetes

175 (7.1%)

Hypertension

808 (32.9%)

Hyperlipidemia

331 (13.5%)

Dyslipidemia

731 (29.7%)

Baseline medication use
Statin use

371 (15.1%)

Aspirin use

569 (23.1%)

Estimated ASCVD risk
10-Year Estimated ASCVD risk,* %

3.96 (4.16)

*Using the Pooled Cohort Equations
Results are presented as either number (%) or mean (standard deviation).
Abbreviations: ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease
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